Shanghai Zhigen Pharmaceutical Technology

Shanghai Zhigen Pharmaceutical Technology is a clinical-stage biotechnology company based in Shanghai, China, dedicated to the discovery and development of innovative small molecule drugs. The company focuses on protein degradation technologies, including Proteolysis-targeting chimeras (PROTACs) and molecular glues, to target previously undruggable proteins. Its lead program, ZG-001, is an oral PROTAC targeting the androgen receptor for the treatment of metastatic castration-resistant prostate cancer. Zhigen Pharma's research and development efforts are primarily centered on oncology and other diseases with significant unmet clinical needs. The company leverages a proprietary platform to rapidly advance candidates from discovery to clinical proof-of-concept. Backed by prominent venture capital firms, Zhigen Pharma aims to provide transformative therapies for patients globally.